Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 915-920

  Blanke, C D ^a   Kasimis, B ^a   Schein, P ^a   Capizzi, R ^a   Kurman, M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; TRIMETREXATE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNE DEFICIENCY; INOPERABLE CANCER; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME;

EID: 0031056423     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.915     Document Type: Article

References (32)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics. CA 46:5-27, 1996
2. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
3. Conti JA, Kemeny N, Saltz L, et al: Irinotecan (CPT-11) is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709-715, 1996
4. Zalcberg J, Cunningham D, Van Cutsem E, et al: ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 14:716-721, 1996
5. Brown TD, Fleming TR, Goodman PJ, et al: A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: A Southwest Oncology Group study. Anticancer Drugs 6:219-223, 1995
6. Hudes GR, Comis RL: Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil to patients with metastatic cancer. Semin Oncol 15:41-45, 1988
7. Conti J, Kemeny N, Seiter K, et al: Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 12:695-700, 1994
8. Jackson RC, Froy DW, Boritzki TJ, et al: Biochemical pharmacology of the lipophilic antifolate, trimetrexate. Adv Enzyme Regul 22:187-206, 1984
9. Weir E, Cashmore A, Dreyer R, et al: Pharmacology and toxicity of a potent "nonclassical" 2,4-diamino quinazoline folate antagonist, trimetrexate, in normal dogs. Cancer Res 42:1696-1702, 1982
10. O'Dwyer P, DeLap R, King S, et al: Trimetrexate: Clinical development of a nonclassical antifolate. NCI Monogr 5:105-109, 1987
11. Kamen B, Cashmore A, Dreyer R, et al: Uptake and efficacy of trimetrexate, a nonclassical antifolate in methotrexate resistant leukemia cells in vitro. Biochem Pharmacol 33:1697-1699, 1984
12. Lin J, Bertino B: Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties. Cancer Invest 9:159-172, 1991
13. Jackson R, Leopold W, Hamelehle K, et al: Preclinical studies with trimetrexate: A review of conclusions and unanswered questions. Semin Oncol 15:1-7, 1988 (suppl 2)
14. Romanini A, Li W, Colofiore J, et al: Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil in CCRF-CEM cells. J Natl Cancer Inst 84:1033-1038, 1992
15. Leichman CG, Fleming TR, Muggia FM, et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13:1303-1311, 1995
16. Panasci L, Ford J, Margolese R: A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer. Cancer Chemother Pharmacol 15:164-166, 1985
17. Hermann R, Spehn J, Beyer JH, et al: Sequential methotrexate and 5-fluorouracil: Improved response rate in metastatic colorectal cancer. J Clin Oncol 2:591-594, 1984
18. Valone FH, Friedman MA, Wittlinger PS, et al: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: A randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427-1436, 1989
19. Stewart JA, McCormack JJ, Tong W, et al: Phase I clinical and pharmacokinetic study of trimetrexate using a daily x 5 schedule. Cancer Res 48:5029-5035, 1988
20. Grochow LB, Noe DA, Ettinger DS, et al: A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: Clinical pharmacology and pharmacodynamics. Cancer Chemother Pharmacol 24:314-320, 1989
21. Bishop JF, Raghavan D, Olver IN, et al: A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion. Cancer Chemother Pharmacol 24:246-250, 1989
22. Jolivet J, Landry L, Pinard MF, et al: A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother Pharmacol 20:169-172, 1987
23. Lin JT, Cashmore AR, Baker M, et al: Phase I studies with trimetrexate: Clinical pharmacology, analytical methodology, and pharmacokinetics. Cancer Res 47:609-616, 1987
24. Reece PA, Morris RG, Bishop JF, et al: Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer. Cancer Res 47:2996-2999, 1987
25. Fanucchi MP, Walsh TD, Fleisher M, et al: Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res 47:3303-3308, 1987
26. Allegra CJ, Jenkins J, Weiss RB, et al: A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule. Invest New Drugs 8:159-166, 1990
27. Grochow LB, Noe DA, Dole GB, et al: Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: Clinical pharmacology and pharmacodynamics. J Natl Cancer Inst 81:124-130, 1989
28. Huan SD, Legha SS, Raber Mn, et al: Phase I studies of trimetrexate using single and weekly dose schedules. Invest New Drugs 9:199-206, 1991
29. Maroun J, Leiby J, Capizzi R, et al: Efficacy of trimetrexate (CI-898, TMTX) in patients with solid tumors. Clin Res 35:529A, 1987 (abstr)
30. Ajani J, Abbruzzese J, Faintuch J, et al: A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. Cancer Invest 8:619-621, 1990
31. Abigerges D, Armand J-P, Chabot GG, et al: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446-449, 1994
32. Buroker, TR, O'Connell MJ, Wieand HS, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1994